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Tumor propagation by cancer stem cells (CSCs) requires their ability to self-renew, and yet the signal
pathways involved in this process remain poorly defined. In the December issue ofCancer Cell, Zhao
et al. (2007) provide compelling evidence that Wnt/b-catenin signaling is crucial for the maintenance
of chronic myelogenous leukemia (CML) stem cells.In recent years, one of the most impor-
tant advances in our understanding of
cancer biology is the realization that
the limitless growth of tumor cells
seen in this disease seems to be main-
tained by a reservoir of cells with
stem cell characteristics. These cells,
termed cancer stem cells (CSCs),
spawn a continuous supply of leuke-
mic clones and are believed to be re-
sponsible for the recurrence of the
disease following anticancer therapy.
One of the main goals in cancer re-
search therefore is the identification
of CSCs. Leukemia has served as a
model disease for studying cancer bi-
ology, and a number of studies have
focused on the identification and char-
acterization of leukemic stem cells
(LSCs) in different leukemia subtypes.
There is now convincing evidence
showing that even though LSCs share
many properties of stem cells, they
can sometimes be distinguished by the
expression of certain surface markers
(Krause and Van Etten, 2007). More-
over, another important aspect is the
elucidation of molecular mechanisms
and signaling pathways that enable
an LSC to self-renew, thereby main-
taining itself and feeding the tumor
bulk. Even though the capability of
self-renewal is believed to be crucial
for LSC maintenance, the underlying
mechanisms remain poorly defined. In-
sights into pathways that govern leu-
kemic self-renewal would facilitate the
development of therapies targeting
these LSC-associated pathways. In
the December issue of Cancer Cell,
Zhao and colleagues (Zhao et al.,2007) report on a conditional b-catenin
knockout model and identify the Wnt/
b-catenin pathway as being essential
for the self-renewal of normal and
chronic myelogenous leukemia (CML)
stem cells.
The Wnt/b-catenin pathway is in-
volved in a number of key develop-
mental processes, and its deregulation
is observed in many types of cancer
(Reya and Clevers, 2005). Because
the deletion of b-catenin, an integral
component of this pathway, is embry-
onic lethal, Reya and colleagues
specifically deleted this gene in he-
matopoietic cells by crossing flox-b-
catenin mice with vav-Cre mice. They
showed that b-catenin-depleted HSCs
are unchanged compared to normal
HSCs with regard to distribution in
the cell cycle, multilineage differentia-
tion, and homing ability, but that these
HSCs are clearly impaired in their self-
renewal capacity. The authors then
employed this model for the assess-
ment of leukemia induction by the
BCR-ABL fusion gene, which has
been shown to induce CML and acute
lymphocytic leukemia (ALL) in mice
(Li et al., 1999). Importantly, loss of b-
catenin impeded the development of
CML and the self-renewal capability
of CML stem cells after retrovirally
enforced expression of BCR-ABL in
bone marrow cells of b-catenin null
mice. These data indicate that the
impairment of HSC self-renewal in
b-catenin/ mice pre-empted the
subversion of this property for the gen-
eration of CML LSCs (Figure 1). This
finding is in line with previous dataCell Stem Cell 1,showing that BCR-ABL cannot trans-
form non-self-renewing progenitors
(Huntly et al., 2004). Furthermore, it
was previously demonstrated that
the acquisition of self-renewal by b-
catenin activation in myeloid progeni-
tors seems to be a crucial event in
the evolution of chronic phase CML
to blast crisis CML (Jamieson et al.,
2004). The notion that the leukemo-
genic potential of oncogenes is depen-
dent on signaling pathways that are
essential for stem cell self-renewal is
supported by data in an acute myeloid
leukemia (AML) model that showed
the requirement of the polycomb group
gene Bmi-1, a critical regulator of stem
cell self-renewal, for the maintenance
of AML LSCs (Lessard and Sauva-
geau, 2003). These data confirm the
observations that normal and tumor
stem cells share overlapping pro-
grams (Krivtsov et al., 2006) driven by
common genetic determinants.
Strikingly, Zhao et al. (2007) showed
that the development of BCR-ABL-
positive B-ALL as well as the in vivo
self-renewal of B-ALL LSCs was un-
hindered in the absence of b-catenin,
suggesting the involvement of a dis-
tinct self-renewal pathway inBCR-ABL-
positive B-ALL LSCs. Self-renewal is
known to be a complex process in-
volving multiple molecular networks
such as the Polycomb/Trithorax
group, the CDX/HOX genes, and the
Hedgehog, Notch, and Wnt signaling
pathways. Therefore it is conceivable
that the self-renewal of LSCs presum-
ably originating from different cell
stages (such as BCR-ABL-mediatedDecember 2007 ª2007 Elsevier Inc. 597
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B-ALL from a B cell precursor) is gov-
erned by different mechanisms. These
results also highlight the need to iden-
tify LSC-specific pathways separately
for different leukemia subtypes, as
suggested by Zhao et al. (2007), and
even for different developmental
stages of the same molecular subtype
of leukemia.
These findings have important clini-
cal implications, as they turn the spot-
light on the Wnt signaling pathway as
a major player in the self-renewal of
CML LSCs and as a potentially impor-
tant target for the eradication of this
disease. It will be interesting to see
whether these results can be applied
to other cancers as well, especially
because activated Wnt signaling has
been observed in tumors of various tis-
sues (reviewed in Willert and Nusse,
1998; Reya and Clevers, 2005). Even
though the potential use of Wnt inhibi-
tors holds the promise of inducing clin-
ical remission in patients with aber-
rantly activated Wnt signaling, the
shared dependence of normal and tu-
mor stem cells on this pathway might
be detrimental to the selective target-
ing of CSCs, underlining the need for
identifying CSC-specific pathways.
Recently Van Etten and colleagues
(Krause et al., 2006) have shown that
the homing and engraftment of BCR-
ABL-positive stem cells, unlike their
normal counterparts, is dependent on
the adhesion molecule CD44 and that
the deletion of this gene leads to
the abrogation of BCR-ABL-mediated
CML induction in mice. These results
underscore the point that multiple
avenues could be pursued for LSC
eradication in CML.
CML, probably more than any other
cancer, has continued to provide us
Figure 1. Activated Wnt Signaling in CML Development
(A) A depiction of the normal process of HSC self-renewal and myeloid differentiation.
(B) Expression of BCR-ABL in normal HSCs gives rise to CML generating abnormally proliferating
myeloid cells.
(C) The depletion of b-catenin, a key mediator of Wnt signaling, impairs self-renewal and the
ability of BCR-ABL to induce CML, thus characterizing this pathway as a potential target of
CML therapies.598 Cell Stem Cell 1, December 2007 ª2007 Elsevier Inc.with valuable insights into the biology
of malignant tumors. In several ways,
this disease might serve as a paradig-
matic model for other human cancers:
the involvement of a renegade tissue
stem cell that is responsible for a hy-
perproliferative state and the subse-
quent, stepwise acquisition of addi-
tional mutations in these stem cells or
their progeny, resulting in progression
to a more aggressive form of the dis-
ease. Some years ago, the develop-
ment of oncogene-specific molecular
therapy in CML paved the way for the
exploration of similar ‘‘rational drug
design’’ strategies in other neoplastic
disorders. Continuing in this tradition,
valuable insights into CSC biology
emerging from these studies in CML
could expedite the development of
CSC-specific drugs in multiple human
malignancies.
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